References
- Jiang W, Wang H, Li YS, et al. Role of vasoactive intestinal peptide in osteoarthritis. J Biomed Sci. 2016;23:63.
- Cheng C, Zhang FJ, Tian J, et al. Osteopontin inhibits HIF-2α mRNA expression in osteoarthritic chondrocytes. Exp Ther Med. 2015;9:2415–2419.
- Jiang SD, Lu J, Deng ZH, et al. Long noncoding RNAs in osteoarthritis. Joint Bone Spine 2016. Forthcoming. doi: 10.1016/j.jbspin.2016.09.006.
- Pérez MÁ. [Symptoms. Localizations: knee, hip, hands, spine, other localizations]. Aten Primaria. 2014;46:11–17.
- Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646–656.
- Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. Lancet. 2015;386:376–387.
- Brandt KD, Dieppe P, Radin E. Etiopathogenesis of osteoarthritis. Med Clin North Am. 2009;93:1–24.
- Mas Garriga X. [Definition, etiology, classification and presentation forms]. Aten Primaria. 2014;46:3–10.
- Vargas NF, Medina Abellán MD, Hermosa Hernán JC, et al. Treatment of patients with osteoarthritis. Aten Primaria. 2014;46:39–61.
- Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18:476–499.
- Buttgereit F, Burmester GR, Bijlsma JW. Non-surgical management of knee osteoarthritis: where are we now and where do we need to go? RMD Open. 2015;1:e000027.
- Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323–1330.
- Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005;365:965–973.
- Wyles CC, Houdek MT, Behfar A, et al. Mesenchymal stem cell therapy for osteoarthritis: current perspectives. Stem Cells Cloning. 2015;8:117–124.
- Cheng C, Gao S, Lei G. Association of osteopontin with osteoarthritis. Rheumatol Int. 2014;34:1627–1631.
- Hosseinzadeh A, Kamrava SK, Joghataei MT, et al. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res. 2016;61:411–425.
- Yu SM, Kim SJ. Production of reactive oxygen species by withaferin A causes loss of type collagen expression and COX-2 expression through the PI3K/Akt, p38, and JNK pathways in rabbit articular chondrocytes. Exp Cell Res. 2013;319:2822–2834.
- van der Kraan PM, van den Berg WB. Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthr Cartil. 2012;20:223–232.
- Bouaziz W, Funck-Brentano T, Lin H, et al. Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways. Arthritis Res Ther. 2015;17:24.
- Sabapathy K. Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci. 2012;106:145–169.
- Baker AR, Harte AL, Howell N, et al. Epicardial adipose tissue as a source of nuclear factor-kappaB and c-Jun N-terminal kinase mediated inflammation in patients with coronary artery disease. J Clin Endocrinol Metab. 2009;94:261–267.
- Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–549.
- Li YS, Deng ZH, Zeng C, et al. JNK pathway in osteosarcoma: pathogenesis and therapeutics. J Recept Signal Transduct Res. 2016;36:465–470.
- Wang F, Murrell GA, Wang MX. Oxidative stress-induced c-Jun N-terminal kinase (JNK) activation in tendon cells upregulates MMP1 mRNA and protein expression. J Orthop Res. 2007;25:378–389.
- Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 2005;15:36–42.
- Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239–252.
- Yu C, Minemoto Y, Zhang J, et al. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell. 2004;13:329–340.
- Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol. 2007;19:142–149.
- Tournier C. The 2 faces of JNK signaling in cancer. Genes Cancer. 2013;4:397–400.
- Fleming Y, Armstrong CG, Morrice N, et al. Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem J. 2000;352:145–154.
- Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol. 2014;171:24–37.
- Loeser RF, Chubinskaya S, Pacione C, et al. Basic fibroblast growth factor inhibits the anabolic activity of insulin-like growth factor 1 and osteogenic protein 1 in adult human articular chondrocytes. Arthritis Rheum. 2005;52:3910–3917.
- Im HJ, Muddasani P, Natarajan V, et al. Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase Cdelta pathways in human adult articular chondrocytes. J Biol Chem. 2007;282:11110–11121.
- Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta. 2007;1773:1341–1348.
- Loeser RF, Erickson EA, Long DL. Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol. 2008;20:581–586.
- Yang P, Tan J, Yuan Z, et al. Expression profile of cytokines and chemokines in osteoarthritis patients: proinflammatory roles for CXCL8 and CXCL11 to chondrocytes. Int Immunopharmacol. 2016;40:16–23.
- Yaykasli KO, Hatipoglu OF, Yaykasli E, et al. Leptin induces ADAMTS-4, ADAMTS-5, and ADAMTS-9 genes expression by mitogen-activated protein kinases and NF-ĸB signaling pathways in human chondrocytes. Cell Biol Int. 2015;39:104–112.
- Hui W, Litherland GJ, Elias MS, et al. Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis. 2012;71:455–462.
- Hwang SG, Yu SS, Poo H, et al. c-Jun/activator protein-1 mediates interleukin-1beta-induced dedifferentiation but not cyclooxygenase-2 expression in articular chondrocytes. J Biol Chem. 2005;280:29780–29787.
- Henrotin Y, Pesesse L, Lambert C. Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis. Ther Adv Musculoskelet Dis. 2014;6:20–34.
- Cheng J, Hu X, Dai L, et al. Inhibition of transforming growth factor β-activated kinase 1 prevents inflammation-related cartilage degradation in osteoarthritis. Sci Rep. 2016;6:34497.
- Chen S, Fang XQ, Zhang JF, et al. Lycorine protects cartilage through suppressing the expression of matrix metalloproteinases in rat chondrocytes and in a mouse osteoarthritis model. Mol Med Rep. 2016;14:3389–3396.
- Wei B, Bai X, Chen K, et al. SP600125 enhances the anti-apoptotic capacity and migration of bone marrow mesenchymal stem cells treated with tumor necrosis factor-α. Biochem Biophys Res Commun. 2016;475:301–307.
- Ma C, Zhang Y, Li YQ, et al. The role of PPARγ in advanced glycation end products-induced inflammatory response in human chondrocytes. PLoS One. 2015;10:e0125776.
- Tsou HK, Chen HT, Chang CH, et al. Apoptosis signal-regulating kinase 1 is mediated in TNF-α-induced CCL2 expression in human synovial fibroblasts. J Cell Biochem. 2012;113:3509–3519.
- Kimura H, Yukitake H, Suzuki H, et al. The chondroprotective agent ITZ-1 inhibits interleukin-1beta-induced matrix metalloproteinase-13 production and suppresses nitric oxide-induced chondrocyte death. J Pharmacol Sci. 2009;110:201–211.
- Zayed N, Li X, Chabane N, et al. Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. Arthritis Res Ther. 2008;10:R146.
- Xu W, Xie Y, Wang Q, et al. A novel fibroblast growth factor receptor 1 inhibitor protects against cartilage degradation in a murine model of osteoarthritis. Sci Rep. 2016;6:24042.
- Jeong JW, Lee HH, Choi EO, et al. Schisandrae Fructus inhibits IL-1β-induced matrix metalloproteinases and inflammatory mediators production in SW1353 human chondrocytes by suppressing NF-κB and MAPK activation. Drug Dev Res. 2015;76:474–483.
- Liu SC, Lee HP, Hung CY, et al. Berberine attenuates CCN2-induced IL-1β expression and prevents cartilage degradation in a rat model of osteoarthritis. Toxicol Appl Pharmacol. 2015;289:20–29.
- Lu S, Xiao X, Cheng M. Matrine inhibits IL-1β-induced expression of matrix metalloproteinases by suppressing the activation of MAPK and NF-κB in human chondrocytes in vitro. Int J Clin Exp Pathol. 2015;8:4764–4772.
- Jeong JH, Moon SJ, Jhun JY, et al. Eupatilin exerts antinociceptive and chondroprotective properties in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes. PLoS One. 2015;10:e0130882.
- Li Z, Meng D, Li G, et al. Celecoxib combined with diacerein effectively alleviates osteoarthritis in rats via regulating JNK and p38MAPK signaling pathways. Inflammation. 2015;38:1563–1572.
- Lim HD, Kim YS, Ko SH, et al. Cytoprotective and anti-inflammatory effects of melatonin in hydrogen peroxide-stimulated CHON-001 human chondrocyte cell line and rabbit model of osteoarthritis via the SIRT1 pathway. J Pineal Res. 2012;53:225–237.
- Kim JH, Huh JE, Baek YH, et al. Effect of Phellodendron amurense in protecting human osteoarthritic cartilage and chondrocytes. J Ethnopharmacol. 2011;134:234–242.
- Wen ZH, Tang CC, Chang YC, et al. Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes. Osteoarthr Cartil. 2010;18:1192–1202.
- Wen ZH, Tang CC, Chang YC, et al. Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats. Osteoarthr Cartil. 2013;21:1976–1986.
- Lu H, Hou G, Zhang Y, et al. c-Jun transactivates PUMA gene expression to promote osteoarthritis. Mol Med Rep. 2014;9:1606–1612.
- Ye Z, Chen Y, Zhang R, et al. c-Jun N-terminal kinase – c-Jun pathway transactivates Bim to promote osteoarthritis. Can J Physiol Pharmacol. 2014;92:132–139.
- Ho LJ, Hung LF, Liu FC, et al. Ginkgo biloba extract individually inhibits JNK activation and induces c-Jun degradation in human chondrocytes: potential therapeutics for osteoarthritis. PLoS One. 2013;8:e82033.
- Singh R, Ahmed S, Malemud CJ, et al. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res. 2003;21:102–109.
- Akhtar N, Haqqi TM. Epigallocatechin-3-gallate suppresses the global interleukin-1beta-induced inflammatory response in human chondrocytes. Arthritis Res Ther. 2011;13:R93.
- Zeng L, Wang W, Rong XF, et al. Chondroprotective effects and multi-target mechanisms of Icariin in IL-1 beta-induced human SW 1353 chondrosarcoma cells and a rat osteoarthritis model. Int Immunopharmacol. 2014;18:175–181.
- Huh JE, Seo BK, Baek YH, et al. Standardized butanol fraction of WIN-34B suppresses cartilage destruction via inhibited production of matrix metalloproteinase and inflammatory mediator in osteoarthritis human cartilage explants culture and chondrocytes. BMC Complement Altern Med. 2012;12:256.
- Phitak T, Pothacharoen P, Settakorn J, et al. Chondroprotective and anti-inflammatory effects of sesamin. Phytochemistry. 2012;80:77–88.
- Smith MM, Russell AK, Schiavinato A, et al. A hexadecylamide derivative of hyaluronan (HYMOVIS®) has superior beneficial effects on human osteoarthritic chondrocytes and synoviocytes than unmodified hyaluronan. J Inflamm (Lond). 2013;10:26.